LEO Pharma A/S, a global leader in medical dermatology, today presented late-breaking data showcasing responses in a subgroup of patients from the DELTA 1 and 2 trials at the 83 rd American Academy of ...

Alongside this presentation, new systemic exposure data has also been shared for delgocitinib cream at the meeting. 2 "The data unveiled today further contributes to LEO Pharma’s ever-growing ...

A new survey commissioned by Leo Pharma confirms there’s plenty of room in the market for its chronic hand eczema treatment ...

1 Separate data presented at the American Academy of Dermatology (AAD) 2025 Annual Meeting evaluated systemic exposure in patients following high use of delgocitinib cream to treat moderate to severe ...

LEO’s topical cream formulation of the pan-JAK inhibitor proved to be more effective than oral therapy alitretinoin in the DELTA FORCE study, which involved adults with moderate to severe CHE.

Leo Dryfruits & Spices Trading Limited, (BSE: 544329), One of the trusted names in the sourcing, processing, trading, and ...